Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia.

Autor:	Osborne RJ; Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; the NRG Oncology Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, New York; Spectrum Health Medical Group, Grand Rapids, Michigan; the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; the University of Colorado Cancer Center, Aurora, Colorado; New Britain General Hospital, Plainville, Connecticut; Women's Cancer Center, Las Vegas, Nevada; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California; Royal Hallamshire Hospital, Sheffield, United Kingdom; and the University of Texas Southwestern Medical Center, Dallas, Texas., Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, Spirtos NM, Chan JK, Tidy JA, Miller DS
Jazyk:	angličtina
Zdroj:	Obstetrics and gynecology [Obstet Gynecol] 2016 Sep; Vol. 128 (3), pp. 535-542.
DOI:	10.1097/AOG.0000000000001554
Abstrakt:	Objective: To evaluate the efficacy and safety of second uterine curettage in lieu of chemotherapy for patients with low-risk, nonmetastatic gestational trophoblastic neoplasia (GTN) and to evaluate whether response to second curettage is independent of patient age, World Health Organization (WHO) risk score, registration human chorionic gonadotropin (hCG) level, lesion size, and depth of myometrial invasion measured on ultrasound examination. Methods: This was a cooperative group multicenter prospective phase II study. Prestudy testing included quantitative hCG level, pelvic ultrasonography, and chest radiography. Patients were categorized according to WHO risk scoring criteria (low risk with a score of 0-6). Results: Sixty-four women with newly diagnosed low-risk, nonmetastatic GTN were enrolled. Four patients were excluded. Twenty-four patients (40%) (lower 95% confidence limit 27.6%) were cured after second curettage. An additional two patients (3%) achieved a complete response but did not complete follow-up. Overall, 26 of 60 patients were able to avoid chemotherapy. Surgical failure was observed in 34 women (59%) and was more common in women 19 years old or younger or 40 years old or older. One case of grade 1 uterine perforation was successfully managed by observation. Four grade 1 and one grade 3 uterine hemorrhages were reported. New metastatic disease (lung) was identified in one of these women after second curettage. In three patients (surgical failures), the second curettage pathology was placental site trophoblastic tumor, and it was placental nodule in one additional patient. Conclusion: Second uterine curettage as initial treatment for low-risk, nonmetastatic GTN cures 40% of patients without significant morbidity. Clinical Trial Registration: ClinicalTrials.gov, https://clinicaltrials.gov/, NCT00521118.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu